AFT Pharmaceuticals Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de AFT Pharmaceuticals de 19.3% y 13% por año respectivamente. Se prevé que el BPA crezca en un 14.3% al año. Se espera que la rentabilidad financiera sea de 19.3% en 3 años.

Información clave

19.3%

Tasa de crecimiento de los beneficios

14.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	25.7%
Tasa de crecimiento de los ingresos	13.0%
Rentabilidad financiera futura	19.3%
Cobertura de analistas	Low
Última actualización	02 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21

Previsiones de crecimiento de beneficios e ingresos

NZSE:AFT - Estimaciones futuras de los analistas y datos financieros pasados (NZD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	311	24	34	N/A	1
3/31/2026	257	24	23	17	3
3/31/2025	220	17	8	12	3
3/31/2024	193	15	8	14	3
9/30/2023	175	11	4	13	N/A
6/30/2023	166	11	3	12	N/A
3/31/2023	157	11	2	12	N/A
12/31/2022	149	14	4	12	N/A
9/30/2022	141	17	6	13	N/A
6/30/2022	135	18	7	14	N/A
3/31/2022	130	20	9	14	N/A
12/31/2021	125	15	7	12	N/A
9/30/2021	120	11	5	10	N/A
6/30/2021	116	9	0	6	N/A
3/31/2021	113	8	-5	1	N/A
12/31/2020	110	5	-4	3	N/A
9/30/2020	107	3	-2	6	N/A
6/30/2020	107	7	3	10	N/A
3/31/2020	106	12	8	15	N/A
12/31/2019	100	11	7	12	N/A
9/30/2019	94	11	5	9	N/A
6/30/2019	89	4	1	5	N/A
3/31/2019	85	-3	-2	1	N/A
12/31/2018	84	-7	-5	-1	N/A
9/30/2018	83	-11	-8	-4	N/A
6/30/2018	82	-12	-10	-6	N/A
3/31/2018	81	-14	-12	-9	N/A
12/31/2017	79	-14	-15	-13	N/A
9/30/2017	76	-14	-17	-16	N/A
6/30/2017	73	-16	N/A	-18	N/A
3/31/2017	69	-18	N/A	-19	N/A
12/31/2016	67	-18	N/A	-20	N/A
9/30/2016	64	-18	N/A	-21	N/A
6/30/2016	64	-16	N/A	-17	N/A
3/31/2016	64	-13	N/A	-14	N/A
12/31/2015	63	-13	N/A	-12	N/A
9/30/2015	62	-13	N/A	-10	N/A
6/30/2015	59	-13	N/A	-11	N/A
3/31/2015	56	-13	N/A	-13	N/A
3/31/2014	49	-1	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (19.3% al año) de AFT es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (19.3% al año) de AFT crezcan más rápidamente que el mercado NZ (17.7% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de AFT crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (13% al año) de AFT crezcan más rápidamente que los del mercado NZ (5.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 13% al año) de AFT crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de AFT sea baja dentro de 3 años (19.3%).

AFT Pharmaceuticals Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates fall by 17%

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

Price target decreased to NZ$4.22

Recent updates

AFT Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 23, 2024

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Announces Board Changes

Independent Non-Executive Director recently sold NZ$109k worth of stock

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Consensus EPS estimates fall by 17%

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

Price target decreased to NZ$4.22

Consensus forecasts updated

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Price target decreased to NZ$5.51

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

AFT Pharmaceuticals Limited Update on Maxigesic IV Us Registration Filing

AFT Pharmaceuticals Limited Completes Pascomer Clinical Study

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

US FDA Seeks More Information on AFT Pharmaceuticals Limited's Maxigesic IV Application

Price target decreased to NZ$4.40

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Investor sentiment improved over the past week

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year to 31 March 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

Price target increased to NZ$5.88

AFT Pharmaceuticals Announces US Food and Drug Administration Approve Topical Treatment Indicated for Facial Angiofibroma

Independent Director recently bought NZ$66k worth of stock

Independent Director recently bought NZ$171k worth of stock

AFT Pharmaceuticals Limited Welcomes Australian Federal Court Appeal Success

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

First half 2022 earnings released: EPS NZ$0.04 (vs NZ$0.01 in 1H 2021)

Price target increased to NZ$5.88

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

AFT Pharmaceuticals Got First Regulatory Approval of Maxigesic Oral Liquid in Europe

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Full year 2021 earnings released

AFT Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year 2022

CFO & Company Secretary exercised options to buy NZ$205k worth of stock.

Consensus EPS estimates fall to NZ$0.092

Price target decreased to NZ$4.95

AFT Pharmaceuticals Revises Earnings Guidance for the Year to 31 March 2021

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

AFT Pharmaceuticals Signs an Exclusive Maxigesic IV Licensing Agreement for Eight New European Markets

New 90-day low: NZ$4.21

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

New 90-day high: NZ$5.51

AFT Pharmaceuticals Limited Appoints Anita Baldauf as Non-Executive Director

New 90-day low: NZ$4.55

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Analysts lower EPS estimates to NZ$0.11

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Revenue and earnings miss expectations

AFT Pharmaceuticals Limited Appoints Eddie Townslie as the Local Director of AFT Pharmaceuticals Europe

New 90-day high: NZ$5.46

AFT Pharmaceuticals Receives a US Food and Drug Administration Complete Response Letter Covering Its Application for the Approval of A Tablet Version of Its Maxigesic® Pain Relief Medication

AFT Pharmaceuticals Limited and Setek Sign Supply Agreement

AFT Pharmaceuticals Limited Appoints Anita Baldauf as a Non-Executive Director

AFT Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 19, 2020